iRhythm Technologies Business Summary

iRhythm Technologies (IRTC) operates a service-oriented business model centered on its proprietary Zio platform, which integrates wearable biosensors with cloud-based artificial intelligence to provide ambulatory cardiac monitoring (ACM). The company generates revenue primarily through service fees for its Zio XT, Zio monitor, and Zio AT devices, categorized into Long-Term Continuous Monitoring (LTCM) and Mobile Cardiac Telemetry (MCT) segments. As of early 2026, iRhythm has solidified its market leadership with over 30% share in the core LTCM market, recently achieving free cash flow positivity and guiding for 2026 revenues between $870 million and $880 million. Primary direct competitors include AliveCor, InfoBionic.Ai, and Philips (BioTelemetry); iRhythm maintains a competitive edge through its deep-learning clinical algorithms and an extensive real-world evidence base derived from over 1.4 million patients. The company was founded in 2006 by electrophysiologist Uday Kumar and Chris Jaynes, originating from the Stanford Biodesign Innovation Fellowship. The current leadership team is led by President and CEO Quentin Blackford, who joined in 2021 following a tenure as COO of Dexcom. Key executives include CFO Daniel Wilson (appointed August 2024), CTO Brian Lawrence, PhD (joined April 2025 from Vapotherm), and Chief Medical and Scientific Officer Mintu Turakhia, MD. The Board of Directors is chaired by Abhi Talwalkar and recently added financial veterans Karen McGinnis and Kevin O’Boyle in July 2025. Notable institutional backing includes Synergy Life Science Partners, which remains a significant shareholder, alongside major asset managers such as Vanguard and BlackRock.